Drug Trial Radar · NCT05871905
[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects
Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Jun 19, 2023
Primary completion
Nov 6, 2023
Study completion Jun 20, 2024
Sponsor
- Lead sponsor
- TYK Medicines, IncIndustry
- Sponsor type
- Industry
- First posted
- May 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
\[14 C\] Mass balance clinical trial of TY-9591 in healthy Chinese subjects
Conditions
- Healthy Volunteers
Interventions
TY-9591Drug
C14 TY-9591
Primary outcomes
What the sponsor says the trial is designed to measure.
- The total radioactivity in whole blood and plasma after a single oral administration of 14C TY-9591Time frame: After oral administration of 14C TY-9591, the radiometabolite profiles of plasma, urine and stool were obtained to identify the major metabolites
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Suzhou first people's hospital
Suzhou, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.